CN Patent

CN111454290A — 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途

Assigned to AbbVie Inc · Expires 2020-07-28 · 6y expired

What this patent protects

本发明涉及卡比多巴和左旋多巴前药及它们治疗帕金森病的用途。本公开涉及(a)卡比多巴前药，(b)包含卡比多巴前药和/或左旋多巴前药的药物组合产品和组合物，和(c)治疗帕金森病和相关病症的方法，所述方法包括给予患有帕金森病的对象卡比多巴前药和左旋多巴前药。

USPTO Abstract

本发明涉及卡比多巴和左旋多巴前药及它们治疗帕金森病的用途。本公开涉及(a)卡比多巴前药，(b)包含卡比多巴前药和/或左旋多巴前药的药物组合产品和组合物，和(c)治疗帕金森病和相关病症的方法，所述方法包括给予患有帕金森病的对象卡比多巴前药和左旋多巴前药。

Drugs covered by this patent

Patent Metadata

Patent number
CN111454290A
Jurisdiction
CN
Classification
—
Expires
2020-07-28
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.